The impact of (1:1) XXXX conversion to its microemulsion formulation on the kidney function of @entity1 with cardiac allografts.

@entity1 @entity2246 @entity177 @entity205 @entity972 @entity1011 @entity165 @entity414
Due to the large variations in the absorption and bioavailability of conventional @entity205 (CyA), 1:1 (mg:mg) conversion to its microemulsion formulation (Neoral) has been advocated in transplant recipients. However, the renal hazards and biochemical effects of such conversions and not known in cardiac transplant recipients. In this study, 68 cardiac transplant recipients who were receiving conventional CyA, for a period of 61.3 +/- 36.0 (mean +/- @entity2246 ( @entity2246 )) months, were switched to the microemulsion formulation (Neoral). The biochemical and renal function tests were evaluated at 1, 3, 6, 9 and 12 months pre- and post-conversion of CyA. The results obtained post-conversion were compared with those of the baseline (pre-conversion). Serum @entity1011 and @entity414 levels significantly increased post-conversion to the microemulsion formulation. One @entity1 required discontinuation of the microemulsion in an attempt to reverse severe @entity177 . In spite of a significant decrease in the microemulsion dose at 6, 9 and 12 months, there was a significant increase in the whole blood CyA trough levels at 9 and 12 months of conversion. There was no significant change in blood pressure, serum total @entity165 or @entity972 post-conversion. Our results suggest that after 1:1 (mg:mg) conversion of CyA to its microemulsion formulation, there will be a significant rise in serum @entity1011 , @entity414 and whole blood trough CyA levels necessitating significant dose reduction. This effect is probably due to the markedly improved absorption and bioavailability of the latter.
